The GLP is committed to full transparency. Download and review our Annual Report.

Bayer’s takeover of Monsanto hits US anti-trust snag

| | March 16, 2018

Bayer AG’s plan to win antitrust approval for its takeover of Monsanto Co. hasn’t satisfied U.S. officials who are worried the merger could hurt competition, according to two people familiar with the matter.

The Justice Department’s antitrust division doesn’t think Bayer’s proposal to sell businesses goes far enough, said the people. The government wants the German chemicals company to divest more assets to resolve its concerns, said one of the people, who asked not to be named because the investigation is confidential.

Negotiations between the two sides are continuing and a final decision by the government is probably months away, the person said. Talks have been constructive as Bayer has taken steps to address the government’s concerns, the person added.

Bayer’s $66 billion takeover of St. Louis-based Monsanto is part of a wave of consolidation that has swept seed and crop-chemical firms. The companies are seeking approval from U.S. and European officials after two previous deals – the combination of Dow Chemical Co. and DuPont Co. and China National Chemical Corp.’s takeover of Syngenta AG – won antitrust clearance.

 

Read full, original post: Bayer Faces U.S. Hurdles for Monsanto Antitrust Nod

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend